Accenture – Life Sciences & GenAI, 2024

The authors introduce the concept of using generative AI for innovation in the life sciences industry in 2024. They pose questions about the potential benefits such as developing new medicines for previously untreated illnesses, reducing R&D costs, optimizing manufacturing, and anticipating market events. The 2023 strategy of Total Enterprise Reinvention for Biopharma is referenced as a way for companies to embrace change and drive innovation. The authors highlight the importance of utilizing technology, data, and AI for continuous reinvention to stay ahead in the competitive landscape. They stress the significance of embracing disruptive technologies like generative AI and provide a recommended approach for companies to achieve sustainable growth and financial benefits. The report presents "The Why, What, and How" of continuous reinvention in the era of generative AI for companies in the life sciences sector.